Damora Therapeutics, Inc. DMRA

Full chart Compare
Set alert

Price alert · DMRA

All alert types
22.08 USD +0.48 (+2.22%)

At closeNov 3, 2026, 4:01 PM EST

22.08 0.00 0.00%

After hours · Nov 3, 4:01 PM ET

21.70 Day range 22.77
4.95 52-week range 38.33
YTD
-4.04%
1 year
+229.55%

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 46.89 +112.4% upside
Target (low)
40.00
Target (mean)
46.89
Target (high)
60.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy9
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 10
  • 1 month ago 10
  • 2 months ago 10

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

DMRA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.435-0.53 – -0.370.000.0%00.0%4
Next quarter-0.4725-0.59 – -0.380.000.0%00.0%4
Current year-1.90-2.34 – -1.600.000.0%00.0%4
Next year-2.17-2.59 – -1.59-1.90-14.6%00.0%4

Upgrades and downgrades

The latest rating changes

DMRA analyst upgrades and downgrades
DateFirmActionFromTo
Sep 29, 2026WedbushReiteratedOutperformOutperform
Sep 25, 2026GuggenheimMaintainedBuyBuy
Jul 30, 2026WedbushMaintainedOutperformOutperform
Jul 27, 2026JefferiesInitiated—Buy
Jul 21, 2026HC Wainwright & Co.ReiteratedBuyBuy
Jun 12, 2026WedbushReiteratedOutperformOutperform
Jun 11, 2026HC Wainwright & Co.Initiated—Buy
May 28, 2026WedbushInitiated—Outperform
Apr 24, 2026RBC CapitalInitiated—Outperform
Mar 25, 2026Evercore ISI GroupInitiated—Outperform
Feb 17, 2026UBSInitiated—Buy
Feb 17, 2026GuggenheimMaintainedBuyBuy
Jan 7, 2026Leerink PartnersInitiated—Outperform
Dec 8, 2025GuggenheimMaintainedBuyBuy
Dec 1, 2025GuggenheimInitiated—Buy